

Supplemental material

Jacobsen et al., <https://doi.org/10.1084/jem.20172064>





Figure S1. Sequence of the *Igh^{CGG}* insertion. Terminal ends of the 5' (long) and 3' (short) arms of homology are shown in blue. The recoded leader for the anti CGG VJ is shown in green, with altered bases indicated in lowercase letters. The coding sequence for human Igk is shown in orange, with silent mutations used to eliminate AID hotspots indicated as lowercase letters. The splice donor (sd) site is indicated in the 3' untranslated region of anti-CGG VDJ.



P2A cleavage site

P2A: ATNFSLLKQAGDVEENPGP

Figure S2. Partial sequence of the light chain plasmid used for recombinant antibody production. The C-terminal P2A sequence of the human Igk constant, after cleavage, is marked in red and indicated with the cleavage site under the sequence.

Table S1. Reagents used for flow cytometry

| Surface molecule | Fluorochrome | Clone | Manufacturer | Product number | Final concentration ($\mu\text{g}/\text{ml}$) |
|--------------------|---------------------|-----------|----------------|----------------|---|
| Human Igk | PE | MHK-49 | BioLegend | 316508 | 5 $\mu\text{l}/\text{test}$ |
| CD19 | BV 650 | 1D3 | BD Biosciences | 563235 | 1 |
| CD45R/B220 | BV 421 | RA3-6B2 | BioLegend | 103240 | 0.5 |
| CD45R/B220 | PerCP/CY5.5 | RA3-6B2 | BioLegend | 103236 | 0.5 |
| CD45R/B220 | BV 605 | RA3-6B2 | BioLegend | 103244 | 0.5 |
| CD45R/B220 | FITC | RA3-6B2 | BioLegend | 103206 | 0.5 |
| CD4 | BV 785 | RM4-5 | BioLegend | 100551 | 0.5 |
| IgM | PE | RMM-1 | BioLegend | 406508 | 0.5 |
| IgM | PE/CY7 | II/41 | eBioscience | 25-5790-81 | 0.5 |
| IgG1 | APC | RMG1-1 | BioLegend | 406610 | 0.5 |
| IgD | BV 650 | 11-26c.2a | BioLegend | 405721 | 0.5 |
| CD93 | APC | AA4.1 | BioLegend | 136509 | 1 |
| CD23 | FITC | B3B4 | BioLegend | 101605 | 0.5 |
| CD21 | PE/CY7 | 7E 9 | BioLegend | 123420 | 0.5 |
| Mouse Igk | APC/CY7 | RMK-45 | BioLegend | 409503 | 0.5 |
| TCR β | APC/CY7 | H57-597 | BioLegend | 109220 | 0.5 |
| CD38 | PerCP/CY5.5 | 90 | BioLegend | 102722 | 0.5 |
| FAS | BV 421 | Jo2 | BD Biosciences | 562633 | 0.25 |
| CD45.1 | FITC | A20 | BD Biosciences | 553775 | 0.5 |
| CD45.2 | AF 700 | 104 | BioLegend | 109822 | 0.5 |
| CGG | Biotin ^a | | Rockland | D602-0100 | 10 |
| | SA-BV 421 | | BioLegend | 405225 | 0.25 |
| CD16/32 (Fc block) | — | 2.4G2 | Bio-X-Cell | CUS-HB-197 | 1 |
| CD138 | BV 650 | 281-2 | BioLegend | 142517 | 0.5 |
| CD5 | APC | 53-7.3 | BioLegend | 100626 | 0.5 |
| CD11b | BV 421 | M1/70 | BioLegend | 101236 | 0.5 |

AF, Alexa Fluor; APC, allophycocyanin; APC/Cy7, allophycocyanin/Cyanin7; BV, Brilliant Violet; PerCP/Cy5.5, Peridinin-chlorophyll/Cyanin 5.5; PE/Cy7, PE/Cyanin7; SA, Streptavidin.

^aConjugated to biotin in our laboratory.